MoonLake Immunotherapeutics (MLTX)
NASDAQ: MLTX · Real-Time Price · USD
19.02
-0.34 (-1.76%)
Jul 24, 2026, 4:00 PM EDT - Market closed
MLTX Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Assets
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Equivalents | 298.49 | 334.52 | 180.43 | 451.17 | 39.51 | 8.04 |
Short-Term Investments | 59.43 | 59.45 | 267.6 | 59.84 | 32.61 | - |
Cash & Short-Term Investments | 357.92 | 393.97 | 448.03 | 511.01 | 72.11 | 8.04 |
Cash Growth | -25.45% | -12.07% | -12.32% | 608.60% | 797.08% | 501.74% |
Other Receivables | 5.76 | 4.87 | 2.84 | 1.06 | 0.22 | 0.15 |
Total Trade Receivables | 5.76 | 4.87 | 2.84 | 1.06 | 0.22 | 0.15 |
Other Current Assets | 32.96 | 22.86 | 23.42 | 2.1 | 4.18 | 1.45 |
Total Current Assets | 396.64 | 421.69 | 474.29 | 514.17 | 76.51 | 9.64 |
Net Property, Plant & Equipment | 2.39 | 2.14 | 3.64 | 3.95 | 0.33 | 0.05 |
Other Long-Term Assets | 1.34 | 0.6 | - | 8.42 | - | - |
Total Assets | 400.37 | 424.43 | 477.93 | 526.54 | 76.84 | 9.68 |
Liabilities
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Accounts Payable | 23.38 | 29.55 | 8.99 | 1.84 | 0.25 | - |
Accrued Expenses | 21.81 | 14.69 | 12.1 | 6.93 | 7.26 | 4.52 |
Short-Term Debt | - | - | - | - | - | 15 |
Current Portion of Leases | 0.92 | 1.23 | 1.37 | 1.2 | 0.15 | - |
Total Current Liabilities | 46.11 | 45.48 | 22.46 | 9.97 | 7.67 | 21.09 |
Long-Term Debt | 99.02 | 74.1 | - | - | - | - |
Long-Term Leases | 0.87 | 0.37 | 1.46 | 2.5 | 0.13 | - |
Other Long-Term Liabilities | 0.35 | - | 0.62 | 0.58 | 0.28 | 0.24 |
Total Long-Term Liabilities | 100.24 | 74.47 | 2.08 | 3.08 | 0.41 | 0.24 |
Total Liabilities | 146.35 | 119.95 | 24.54 | 13.05 | 8.08 | 21.33 |
Shareholders' Equity
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Preferred Stock | - | - | - | - | - | 0.07 |
Common Stock | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.04 |
Treasury Stock | - | - | - | - | - | -0.01 |
Additional Paid-in Capital | 786.31 | 766.78 | 677.42 | 609.97 | 129.19 | 42.06 |
Accumulated Other Comprehensive Income | 0.32 | 0.6 | 5 | 2.36 | 0.35 | -0.17 |
Retained Earnings | -532.62 | -462.91 | -235.59 | -116.66 | -80.65 | - |
Total Common Shareholders' Equity | 254.02 | 304.48 | 446.83 | 495.68 | 48.9 | 42 |
Minority Interest | - | - | 6.57 | 17.82 | 19.87 | - |
Shareholders' Equity | 254.02 | 304.48 | 453.39 | 513.49 | 68.77 | 42 |
Total Liabilities & Equity | 400.37 | 424.43 | 477.93 | 526.54 | 76.84 | 9.68 |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Total Debt | 100.8 | 75.71 | 2.83 | 3.7 | 0.28 | 15 |
Net Cash (Debt) | 257.12 | 318.26 | 445.2 | 507.31 | 71.83 | -6.96 |
Net Cash Growth | -36.44% | -28.51% | -12.24% | 606.24% | - | - |
Net Cash Per Share | 3.86 | 4.94 | 7.08 | 10.33 | 1.89 | -0.65 |
Book Value | 254.02 | 304.48 | 446.83 | 495.68 | 48.9 | 42 |
Book Value Per Share | 3.82 | 4.72 | 7.11 | 10.09 | 1.29 | 3.91 |
Tangible Book Value | 254.02 | 304.48 | 446.83 | 495.68 | 48.9 | 42 |
Tangible Book Value Per Share | 3.82 | 4.72 | 7.11 | 10.09 | 1.29 | 3.91 |